BLPH: Bellerophon Therapeutics, Inc. Stock

by  •  • Comments Off on BLPH: Bellerophon Therapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 0.61
Enterprise Value ($M) -3.77
Book Value ($M) 3.72
Book Value / Share 0.30
Price / Book 0.16
NCAV ($M) 3.72
NCAV / Share 0.30
Price / NCAV 0.16

Profitability (mra)
Return on Invested Capital (ROIC) -2.49
Return on Assets (ROA) -0.58
Return on Equity (ROE) -0.87

Liquidity (mrq)
Quick Ratio 3.96
Current Ratio 3.96

Balance Sheet (mrq) ($M)
Current Assets 4.98
Assets 4.98
Liabilities 1.26
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G/A Perceptive Advisors Llc 0.00 -100.00
02-14 13G/A Tang Capital Partners Lp 0.00 -100.00
01-26 13G Lepercq De Neuflize Asset Management LLC 8.40
10-18 13D/A Puissance Life Science Opportunities Fund VI 0.50 0.00
06-09 13G/A Janus Henderson Group Plc 0.00 -100.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2023-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPO
2023-08-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PU
2023-05-15 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT P

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-04-19 4,047 53,937 7.50

(click for more detail)

Similar Companies
BIXT – Bioxytran, Inc. BLFE – BioLife Sciences Inc.
BLMS – Bloomios, Inc. BMMJ – Body and Mind Inc.
BQST – BioQuest Corp.


Financial data and stock pages provided by
Fintel.io

Finpedia: Bellerophon Therapeutics